Phuturdex › Diseases › Myocardial infarction
Drugs in development · updated 30 October 2026
Myocardial infarction: drugs in development
As of 30 October 2026 there are 30 active clinical trials (recruiting or ongoing, phases I–III) on 26 drugs for myocardial infarction. 12 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CSL300 | II–III | 1 | NCT05485961 |
| MLC1501 | II–III | 1 | NCT05046106 |
| Olpasiran | III | 1 | NCT07136012 |
| Pelacarsen | III | 1 | NCT07517263 |
| Ziltivekimab | III | 1 | NCT07301034 |
| L-CarnitineCarnitine | II | 1 | NCT06564909 |
| Orticumab | II | 1 | NCT06927739 |
| VERVE-102 | II | 1 | NCT07839936 |
| Xolatryp | II | 1 | NCT07362446 |
| STX-1150 | I | 1 | NCT07428473 |
| Dapansutrile | Early I | 1 | NCT05880355 |
| Gadolinium DOTA Meglumine | Early I | 1 | NCT02973633 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AspirinVazalore®, Durlaza® | III | 3 | NCT07052799 |
| ColchicineColchicin, Lodoco® | III | 3 | NCT04774159 |
| DapagliflozinForxiga, Dapagliflozin Propanediol | II–III | 3 | NCT06286878 |
| TicagrelorBrilinta®, Brilique® | III | 2 | NCT07257198 |
| CilostazolPletal® | III | 1 | NCT07174414 |
| FexofenadineChildren'S Allegra Hives®, Children'S Allegra Allergy® | III | 1 | NCT07381803 |
| InclisiranLeqvio® | III | 1 | NCT05739383 |
| MontelukastSingulair® | III | 1 | NCT07320625 |
| TenecteplaseTnkase®, Metalyse® | III | 1 | NCT03998319 |
| EmpagliflozinJardiance | II | 2 | NCT07898709 |
| AtorvastatinLipitor, Atorvaliq® | II | 1 | NCT06924684 |
| CyproheptadinePeriactin® | II | 1 | NCT05469165 |
| EplerenoneEpleronone, Inspra® | II | 1 | NCT05198791 |
| Plasma-Lyte A | II | 1 | NCT00936819 |
Sorted by most advanced phase and number of active trials.
All 26 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Myocardial infarction with ST segment elevation 22 drugs
- Cardiogenic shock 13 drugs
- Heart failure 104 drugs
- Inflammation 85 drugs
- Left ventricular dysfunction 10 drugs
- No reflow phenomenon 3 drugs
- Acute coronary syndrome 17 drugs
- Non-ST elevated myocardial infarction 3 drugs
- Hyperlipidemia 26 drugs
- Congenital heart disease 8 drugs
- Cardiomyopathies 23 drugs
Broader categories
- Vascular disease 16 drugs
- Ischemia 5 drugs
- Necrosis 9 drugs
- Myocardial ischemia 6 drugs
- Heart disease 17 drugs
- Cardiovascular disease 71 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009203 “Myocardial Infarction”.